(MENAFN- GlobeNewsWire - Nasdaq) The report highlights opportunities in setting fair-market value compensation for U.S. KOLs in Emergency Medicine to mitigate compliance risks, enhance negotiation strategies, and align fee schedules with market norms. Early engagement with KOLs-ideally before clinical phases 2 and 3-presents a strategic advantage.

Dublin, Nov. 06, 2025 (GLOBE NEWSWIRE) -- The "United States Fair-Market Value Compensation Rates for Emergency Medicine KOLs" report has been added to ResearchAndMarkets's offering.
This report presents fair-market value (FMV) hourly and half-day compensation rates for U.S. KOLs - Emergency Medicine, by percentiles, with averages, for four (4) levels of Thought Leader influences (rare, international, national and local). Thought Leader Compensation US Emergency Medicine.
These defensible market-based rate data are built directly from industry compensation paid to Healthcare Practitioners (HCPs) and Thought Leaders (KOLs). All KOL FMV rates reports represent fair-market value established using our reliable methodology of collecting data from industry professionals involved in defining compensation levels for exchanges with KOLs worldwide.
Establishing fair-market value compensation rates will:

• reduce the external perception of inappropriate inducement and limit regulatory and compliance risks.
• provide an independent reference for negotiations with Thought Leaders (KOLs) and Healthcare Providers (HCPs).
• refine and support the development of fee schedules that are aligned with market conditions.
• competitively position the organization and support good business practices.

The data included in each report are an aggregate of collected data and not individual rates. In no event, companies and individuals who provided the data are identified to protect their identity.
Payments made to physicians and thought leaders have been under scrutiny for a few years and companies have been working to adjust their rates to level with industry standards.
Insight
Research shows that less than 25% of pharmaceutical organizations begin working and involving Key Opinion Leaders during or before the clinical phase. Most - 63% - wait during phases 2 and 3 to start exchanging with Thought Leaders.
Key Topics Covered:

• Research Methodology
• Definitions
• Therapeutic Area
• Thought Leader Levels
• Flat Rates
• Hourly Rates

For more information about this report visit

About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

CONTACT: CONTACT: Laura Wood,Senior Press Manager... For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

MENAFN06112025004107003653ID1110303795